The study, published in the journal Nature Cell Biology, provides new insights into how the ubiquitin-proteasome pathway works and could lead to new treatments for diseases that are caused by the accumulation of damaged proteins.
"Our findings provide a detailed understanding of how the ubiquitin-proteasome pathway functions," said study lead author Dr. Xinzhu Wei, a professor of biochemistry and molecular biology at the University of Texas Southwestern Medical Center. "This knowledge could help us develop new drugs to target this pathway and treat diseases such as cancer, neurodegenerative disorders, and inflammation."
The ubiquitin-proteasome pathway is essential for maintaining the health of cells. It works by tagging damaged proteins with a small molecule called ubiquitin. The ubiquitinated proteins are then recognized by the proteasome, a large protein complex that breaks down the proteins into small peptides.
In the study, the researchers showed that RNF111 and FAM100A work together to ubiquitinate damaged proteins. RNF111 is an enzyme that attaches ubiquitin to proteins, while FAM100A is a scaffold protein that helps to bring RNF111 and the damaged proteins together.
The researchers also showed that RNF111 and FAM100A are essential for the function of the ubiquitin-proteasome pathway. When either protein was depleted, the pathway was unable to break down damaged proteins, leading to the accumulation of these proteins in cells.
The accumulation of damaged proteins can lead to a variety of diseases, including cancer, neurodegenerative disorders, and inflammation. The researchers believe that targeting RNF111 and FAM100A could provide a new way to treat these diseases.
"Our findings suggest that RNF111 and FAM100A are potential targets for new drugs to treat diseases that are caused by the accumulation of damaged proteins," said Dr. Wei. "We are currently developing small molecules that inhibit these proteins and testing their efficacy in animal models of disease."
